Where industry and HHT treatment meet. What better way to discover new treatment devices, targeted drug therapies, genetic diagnostics then by collaborating with global opinion leaders who specialize in HHT. The possibilities are limitless and they start with you!
Welcome to the 14th HHT International Scientific Conference. Cure HHT is excited to host this critically important event. We are grateful for the dedicated and internationally renowned HHT community of clinicians and scientists that share our mission to engage the scientific and medical community, collaborate with multidisciplinary HHT Centers worldwide and educate our community of patients, physicians, academic institutions, professional associations and corporate partners about this disease so that 1.4 million people worldwide affected by HHT are empowered to live a normal life. Visit www.curehht.org.
Vaderis is a clinical stage biotech company focussed on development of new medicines for the treatment of rare diseases associated with vascular malformations. Vaderis’s lead compound is an AKT-inhibitor currently undergoing clinical trials in North America and Europe for the treatment of Hereditary Haemorrhagic Telangiectasia (HHT).
Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.